You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A Miniature Autoinjector for Multicomponent Drugs and Vaccines

    SBC: CREARE LLC            Topic: CBD13106

    Chemical, biological, or toxin attacks in military and civilian settings are a serious and growing concern. Standard first aid for exposure to some chemical warfare agents and toxins includes the immediate administration of relevant antidotes using an autoinjector. When an attack occurs, pre-filled autoinjectors must be immediately available and thus highly portable, and they must be suitable fo ...

    SBIR Phase II 2014 Department of DefenseOffice for Chemical and Biological Defense
  2. Development of a long-acting, injectable controlled release butyrylcholinesterase formulation using predictive modeling.

    SBC: Qrono, Inc.            Topic: CBD13107

    Elevated levels of human butyrylcholinesterase (hBuChE) confer protection from chemical warfare nerve agents and other organophosphorous chemicals. As a prophylactic, the key to enabling this protection is the ability to maintain elevated concentrations of hBuChE in the plasma for days or weeks. Thus far, plasma-derived hBuChE and PEGylated recombinant forms of BuChE (rBuChE) have been tested in ...

    SBIR Phase II 2014 Department of DefenseOffice for Chemical and Biological Defense
  3. Microfiber-Based Closures with Hermetic Sealing for Chem Bio Protective Garments

    SBC: NANOGRIPTECH            Topic: CBD13109

    Hook and loop closures in Army uniforms have been identified as the critical sources of leaks in protective clothing/equipment, which limits the overall protective capability of the ensemble. We demonstrated during Phase I of this project that we can design and fabricate hybrid closure systems which incorporate areas of microfiber adhesive arrays inspired by the foot-hairs found on geckos which ha ...

    SBIR Phase II 2014 Department of DefenseOffice for Chemical and Biological Defense
  4. Hermetic Seals for Chemical/Biological Protective Garments

    SBC: CREARE LLC            Topic: CBD13109

    Interfaces on existing military chemical/biological protection garments are not designed to fully eliminate macroscopic and microscopic air gaps at folds, fabric surfaces, or hook-and-loop closures, and thus do not provide a hermetic barrier against exposure. Creare proposes to develop a hermetic garment closure system that seals macroscopic and microscopic gaps at interfaces and closures and pro ...

    SBIR Phase II 2014 Department of DefenseOffice for Chemical and Biological Defense
  5. CONTRACT # N44CO-2014-00003C P.O.P. 5/15/2014-5/14/2015; IND ENABLING DEVELOPMENT OF NANOGMP: TARGETED; PURPOSE: TO PROVIDE FY14 FUNDING FOR SBIR PHASE II AWARD

    SBC: QUALIBER, INC.            Topic: NCI

    Not Available

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Arise: An Online Relapse Prevention Tool for Substance Abusers

    SBC: 3-C Institute for Social Development, Inc.            Topic: NIDA

    Modify Phase I product and develop the full Arise product. Modify initial prototype based on feedback and fully develop all six modules. PUBLIC HEALTH RELEVANCE

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  7. A Novel Therapeutic for Invasive Candidiasis

    SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Systemic fungal infections are increasingly common, especially in immune compromised patients. While new antifungal drugs have been developed, there is still a high mortality associated with these infections, especiallythose due to Candida albicans, other non-albicans species (NAS). This is due to the limited spectrum of the drugs, significant side effects, as ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Low Cost Head Impact Alert System for Helmeted Sports

    SBC: Simbex LLC            Topic: NICHD

    DESCRIPTION (provided by applicant): The Center for Disease Control (CDC) estimates the yearly incidence of mild Traumatic Brain Injury (mTBI) at approximately 1.2 million cases in the United States alone. Approximately 1/3 of these injuries occur in football. The Principal Objective of this NIH Phase IIb SBIR project is to expand the utility of the current, and now commercially available, InSite ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Development and Utilization of a Novel Aerosol-Generating Technology to Deliver Luc

    SBC: DISCOVERY LABORATORIES, INC.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Respiratory distress syndrome (RDS) is an acute, severe pulmonary disorder that is the leading cause of morbidity and mortality in preterm infants. It is a major healthcare concern - costs associated with treatment of RDS and its complications exceed 2.4 billion annually in the US. Currently, animal-derived surfactants instilled intratracheally via an endotrac ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Gene Based Therapy for Congestive Heart Failure P2 SBIR

    SBC: Nanocor Therapeutics, Inc.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Congestive heart failure is a major cause of morbidity and mortality in the United States. While progress in conventional treatments is making steady and incremental gains to reduce heart failure mortality, there is a critical need to explore new therapeutic approaches. It is now apparent that gene therapy has broader potential in diseases such as congestive he ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government